163 related articles for article (PubMed ID: 26123901)
1. Pathological and prognostic significance of matrix metalloproteinase-2 expression in ovarian cancer: a meta-analysis.
Liu C
Clin Exp Med; 2016 Aug; 16(3):375-82. PubMed ID: 26123901
[TBL] [Abstract][Full Text] [Related]
2. Pathological and prognostic significance of hypoxia-inducible factor 1α expression in epithelial ovarian cancer: a meta-analysis.
Jin Y; Wang H; Liang X; Ma J; Wang Y
Tumour Biol; 2014 Aug; 35(8):8149-59. PubMed ID: 24845029
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of MMP-9 in ovarian cancer: a meta-analysis.
Li LN; Zhou X; Gu Y; Yan J
Asian Pac J Cancer Prev; 2013; 14(7):4107-13. PubMed ID: 23991961
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer.
Sillanpää S; Anttila M; Suhonen K; Hämäläinen K; Turpeenniemi-Hujanen T; Puistola U; Tammi M; Sironen R; Saarikoski S; Kosma VM
Tumour Biol; 2007; 28(5):280-9. PubMed ID: 17962725
[TBL] [Abstract][Full Text] [Related]
5. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
6. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis.
Jia H; Zhang Q; Liu F; Zhou D
Arch Gynecol Obstet; 2017 Mar; 295(3):689-696. PubMed ID: 27995372
[TBL] [Abstract][Full Text] [Related]
8. The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer.
Fu Z; Xu S; Xu Y; Ma J; Li J; Xu P
Int J Gynecol Cancer; 2015 Mar; 25(3):356-62. PubMed ID: 25695542
[TBL] [Abstract][Full Text] [Related]
9. [Expression of matrix metaloproteinase and tissue inhibitors in ovarian tumors].
Cai W; Song JD
Ai Zheng; 2002 Jan; 21(1):91-4. PubMed ID: 12500407
[TBL] [Abstract][Full Text] [Related]
10. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
Gao GL; Liu LD; Zou XS; Chen WX
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):34-8. PubMed ID: 17331419
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis.
Desmeules P; Trudel D; Turcotte S; Sirois J; Plante M; Grégoire J; Renaud MC; Orain M; Têtu B; Bairati I
Hum Pathol; 2015 May; 46(5):739-45. PubMed ID: 25771900
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of matrix metalloproteinase-7 protein expression in esophageal cancer: a meta-analysis.
Miao S; Zhou SY; Han CS; Zhang LN; Sun HB; Yang B
Drug Des Devel Ther; 2015; 9():3729-40. PubMed ID: 26229436
[TBL] [Abstract][Full Text] [Related]
13. Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer.
Vos MC; van der Wurff AA; Bulten J; Kruitwagen R; Feijen H; van Kuppevelt TH; Hendriks T; Massuger LF
Diagn Pathol; 2016 Apr; 11():34. PubMed ID: 27038607
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
15. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
[TBL] [Abstract][Full Text] [Related]
16. Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours.
Kamel H; Abdelazim I; Habib SM; El Shourbagy MAA; Ahmed NS
J Obstet Gynaecol Can; 2010 Jun; 32(6):580-586. PubMed ID: 20569539
[TBL] [Abstract][Full Text] [Related]
17. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic values of MMP-9 expression in ovarian cancer: A study based on bioinformatics analysis and meta-analysis.
Liu C; Shen Y; Tan Q
Int J Biol Markers; 2023 Mar; 38(1):15-24. PubMed ID: 36448239
[TBL] [Abstract][Full Text] [Related]
20. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
